Evidence mapPaperPMID 33094961Full record

ArticleClinical and translational gastroenterology2020

A Preclinical Animal Study of Combined Intragastric Balloon and Duodenal-Jejunal Bypass Liner for Obesity and Metabolic Disease.

Hassan Ghoz, Veeravich Jaruvongvanich, Reem Matar, Azizullah Beran, Daniel B Maselli, Andrew C Storm, Barham K Abu Dayyeh

Open access · goldAbstract read
In one paragraph

Article in Clinical and translational gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Endoscopic Procedures for Weight Loss.Current obesity reports · 2021
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hassan GhozDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Veeravich JaruvongvanichDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Reem MatarDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Azizullah BeranDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Daniel B MaselliDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Andrew C StormDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
Barham K Abu DayyehDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester Minnesota, USA.
WinnMed · US

Funding

Translation CoreP30DK097512 · INDIANA UNIVERSITY INDIANAPOLIS · 2025 to 2025
$1.7M
NIDDK NIH HHS P30 DK097512
6 · The paper itself

Abstract

introductionEndoscopic bariatric and metabolic therapies can potentially reproduce similar gastric and small intestinal anatomic and physiologic manipulations as Roux-en-Y gastric bypass. This proof of concept animal study was aimed to assess the feasibility, safety, efficacy, and impact on gastrointestinal physiology of combined intragastric balloons (IGB) and duodenal-jejunal bypass liner (DJBL) for the treatment of obesity.

methodsFive Ossabaw pigs were fed a high-calorie diet to develop obesity and were randomly assigned to receive IGB or DJBL in sequence. The weight gain rate was calculated. Fasting and postprandial blood samples were drawn before any intervention (serving as the baseline group) and 1 month after second device insertion (serving as the combination group) to measure gut neurohormonal changes and metabolic parameters.

resultsFour pigs successfully received a sequential device insertion. One pig developed duodenal sleeve prolapse that was spontaneously resolved. One pig was early terminated because of developing a central line infection. The rate of weight gain in the combination group (0.63 ± 1.3 kg/wk) was significantly lower than the baseline group (1.96 ± 2.17 kg/wk) and numerically lower than after insertion of the IGB (1.00 ± 1.40 kg/wk) or the DJBL (0.75 ± 2.27 kg/wk) alone. A trend of higher postprandial glucagon-like peptide-1 was observed in the combination group compared with the baseline group. DISCUSSION: A combination of IGB and DJBL is feasible and well tolerated. A strategy of sequential use of these devices might offer a synergistic approach that can enhance weight loss and metabolic outcomes.

Indexed as

Gastric BalloonAnastomosis, Roux-en-YAnimalsBariatric SurgeryCombined Modality TherapyDiet, AtherogenicDiet, High-FatDisease Models, AnimalDuodenumFeasibility StudiesGlucagon-Like Peptide 1JejunumObesity, MorbidPostprandial PeriodProof of Concept StudySwineGlucagon-Like Peptide 1

Identifiers

PMID33094961
PMCPMC7508443
OpenAlexW3208071935

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.